23andMe Investor Presentation Deck

We Are Redefining Healthcare. With Data. At Scale. Empowering Consumers 12.2M Genotyped Customers¹ Enabling Research & Services 4B+ Phenotypic Data Points¹ Developing Therapeutics 40+ Programs² ¹As of December 31, 2021. 2As of March 31, 2021. Programs include collaborated, 100% owned and royalty interest targets. Genetics-based Primary Care Coming Soon FDA Authorized 7 FDA Authorizations Strong Cash Position $586M¹ Copyright © 2022 23and Me, Inc. 23andMe 59

View entire presentation